"It is clear that growth has stalled this year, compounded by margin contaction. Gross Profit Margin is great but the cost of doing business has noticeably increased."
I wouldn't say growth has "stalled"; the top line grew by 9% in each half of FY2024, and they are cycling very strong pcp comparatives (+39% in DH2022 and +16% in JH2023).
As for CoDB, yep, that has ratcheted up, in the last two half years:
CoDB-to-Sales:
DH2022: 27.8%
JH2023: 27.0%
DH2023: 31.7%
JH2024: 29.3%
However, it warrants pointing out that this was influenced to a reasonable degree by investment in "good" costs (i.e., costs which drive development (R&D) and brand awareness (Advertising/Promotional"), which increased by a very hefty 77% in FY2024 vs FY2023.
What one might describe as "bad" costs (i.e., Employment, Administration and Other) grew by 23%, although it is certain that some of these expenses have been incurred in driving longer term growth - setting up shop in the USA doesn't cost zero, that's for sure.
So, it's bit tricky to know whether this is a mediocre, or in fact a very good-quality, result.
Glass half-empty minded folk might quit reasonably view it as a bit of a "gunnah" company.
That certain key executives have significant shareholdings makes me inclined to have a glass half-full mindset.
But the business is obviously at a critical point in its corporate evolution, and the road is littered with the carcasses of failed Australian companies that have sought fortunes in far-flung geographies, so portfolio sizing needs to reflect that.
I suspect it might be one of those situations of a stock becoming an even better investment at a price 40% or 50% higher after some de-risking has occurred.
.
- Forums
- ASX - By Stock
- LBL
- Ann: Update - Dividend/Distribution - LBL
LBL
laserbond limited
Add to My Watchlist
0.00%
!
36.0¢

Ann: Update - Dividend/Distribution - LBL, page-44
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
36.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $42.35M |
Open | High | Low | Value | Volume |
36.0¢ | 36.5¢ | 36.0¢ | $219.3K | 608.4K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 49047 | 36.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
36.5¢ | 18685 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 49047 | 0.360 |
5 | 79787 | 0.355 |
2 | 10132 | 0.350 |
2 | 30030 | 0.345 |
6 | 21741 | 0.340 |
Price($) | Vol. | No. |
---|---|---|
0.365 | 14354 | 1 |
0.370 | 11746 | 2 |
0.380 | 75000 | 2 |
0.385 | 60000 | 2 |
0.390 | 43000 | 1 |
Last trade - 16.10pm 27/06/2025 (20 minute delay) ? |
Featured News
LBL (ASX) Chart |
The Watchlist
PAR
PARADIGM BIOPHARMACEUTICALS LIMITED..
Paul Rennie, MD & Founder
Paul Rennie
MD & Founder
SPONSORED BY The Market Online